Syros Pharmaceuticals in Clinical Supply Agreement With Roche
August 05 2021 - 7:57AM
Dow Jones News
By Chris Wack
Syros Pharmaceuticals Inc. said it has entered into a clinical
supply agreement with Roche Holding AG.
Under the agreement, Syros said it would supply SY-5609, its
oral inhibitor of cyclin-dependent kinase 7, for a combination
dosing cohort in Roche's ongoing Phase 1/1b trial, which is
evaluating multiple targeted therapies or immunotherapy as single
agents or in rational specified combinations in molecularly defined
subsets of colorectal cancer patients.
Under the terms of the agreement, Roche would sponsor and
conduct the Phase 1/1b study to evaluate the safety, tolerability
and preliminary efficacy of the combination and will assume all
costs associated with the study. In exchange for providing SY-5609,
Syros would receive access to the data on SY-5609 in combination
with atezolizumab. Syros retains all rights to SY-5609.
Syros said selective CDK7 inhibition has been shown to target
two fundamental processes in cancer: transcription and cell cycle
control. Research has shown that CDK7 inhibition induces DNA
replication stress and genome instability in preclinical cancer
models, triggering immune-response signaling, which is further
enhanced by the addition of immune-checkpoint blockade.
Syros shares were up 18%, to $5.30, in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
August 05, 2021 07:45 ET (11:45 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Sep 2023 to Sep 2024